NetworkNewsBreaks – Patient Dosing Underway in B
Post# of 69
(Total Views: 162)
Posted On: 10/22/2018 4:04:25 PM
NetworkNewsBreaks – Patient Dosing Underway in BriaCell Therapeutics’ (TSX.V: BCT) (OTCQB: BCTXF) Combination Study with KEYTRUDA® and YERVOY®
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) recently initiated patient dosing in a combination study of lead clinical candidate Bria-IMT with Merck’s (NYSE: MRK) KEYTRUDA® and Bristol-Myers’ (NYSE: BMY) YERVOY®. A recent proof of concept study of Bria-IMT indicated excellent targeted anti-tumor activity and outstanding safety and tolerability in advanced breast cancer patients. An article further discussing the company reads, “BriaCell continues its commitment to exploring new methods of addressing the advanced breast cancer community’s unmet medical needs, and the company is eager to test this novel combination treatment approach and believes that it will offer significant clinical benefits to patients who have advanced breast cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) recently initiated patient dosing in a combination study of lead clinical candidate Bria-IMT with Merck’s (NYSE: MRK) KEYTRUDA® and Bristol-Myers’ (NYSE: BMY) YERVOY®. A recent proof of concept study of Bria-IMT indicated excellent targeted anti-tumor activity and outstanding safety and tolerability in advanced breast cancer patients. An article further discussing the company reads, “BriaCell continues its commitment to exploring new methods of addressing the advanced breast cancer community’s unmet medical needs, and the company is eager to test this novel combination treatment approach and believes that it will offer significant clinical benefits to patients who have advanced breast cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)